

E1  
B2  
8. (Amended) A method as set forth in claim 6, wherein the substance that acts on [the] guanylyl cyclase A natriuretic peptide receptor [, guanylyl cyclase A,] and is able to accelerate production of cyclic guanosine monophosphate is a natriuretic peptide.

Please add new claim 21 as follows:

B3 sub 2  
--21. A method for treatment of chronic heart failure comprising administering a substance that acts on guanylyl cyclase A natriuretic peptide receptor and is able to accelerate production of cyclic guanosine monophosphate to a subject in need of such treatment in an amount effective for treating said chronic heart failure.--

#### REMARKS

Entry of the foregoing, reexamination and reconsideration of the above-identified application, in light of the remarks which follow, are respectfully requested.

Claims 6 and 8 have been amended to recite that the administered substance acts on a "guanylyl cyclase A natriuretic receptor." Claim 6 has also been amended to recite a "method for treatment of cardiac hypertrophy by reducing heart weight not based on diuretic and hypotensive effects." Support for the amendment may be found at the very least at page 14, line 34 - page 15, line 5; page 19, line 35 - page 20, line 11; page 21, line 25- page 22, line 2. In view of this amendment to claim 6, claim 7 has been rewritten as an independent claim.

Prior to addressing the rejections of record, applicants' invention will first be discussed. As recited in the claims, Applicants' invention is directed to a method for treatment of cardiac hypertrophy. Administration of a substance which acts on guanylyl cyclase A, a receptor for